Journals / Journal of Microbiology and Infectious Diseases / 2018 / Cilt: 08 - Sayı: 03

Profile of Person Affected by Leprosy with Clinical Relapse among in High Endemic State of India

Pages
103–107
Publication Date
2018-09-15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

J Microbiol Infect Dis 2018; 8(3):103-107

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Relapse is not an unusual phenomenon in leprosy, there are many predisposing factors which may lead to occurrence of relapse; some of these include the presence of persistent bacilli, drug monotherapy, inadequate or irregular therapy.
📊
Key Findings & Data:Methods: A hospital record based retrospective follow-up study has been performed and 117 relapse cases of leprosy were included.
💡
Conclusion & Impact:J Microbiol Infect Dis 2018; 8(3):103-107
🔬Design:Research Article
📍Scope:2018 Verileri
⚙️Variables:Drug resistance · Disability · Leprosy

Abstract

Objective: Relapse is not an unusual phenomenon in leprosy, there are many predisposing factors which may lead to occurrence of relapse; some of these include the presence of persistent bacilli, drug monotherapy, inadequate or irregular therapy. Patients usually presents with presence of multiple skin lesions and/or thickened nerves, reason for early relapse is probably bacillary persistence due to inadequate treatment and for late relapse due to or re-infection. The objectives of this study are to assess various clinico-epidemiological factors associated with the occurrence of relapses in leprosy patients. Methods: A hospital record based retrospective follow-up study has been performed and 117 relapse cases of leprosy were included. Leprosy relapse cases presented in the study hospital were interviewed using a predesigned and pretested preformed. Each patient was subjected to clinical, bacteriological and disability assessments for diagnosis of relapse and followed until the completion of multi drug therapy. Results: During a study period, relapse was seen more in male as compared to female. The duration between cessation of treatment and re-appearance of new lesions varied from 1 to 33 years. Disability proportion was high among MB patients. Conclusion: Relapse in leprosy should be thoroughly examined and looked for drug resistance. J Microbiol Infect Dis 2018; 8(3):103-107

🔖

Cite This Article

GİTTE, S. V., NİGAM, C., CHAKRABORTY, A. B., KAMBLE, K., SONİ, M., GAHLOT, R. (2018). Profile of Person Affected by Leprosy with Clinical Relapse among in High Endemic State of India. Journal of Microbiology and Infectious Diseases, Cilt: 08 - Sayı: 03, 103–107. https://ajindex.com/articles/48198

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Kaimal S, Thappa DM. Relapse in leprosy. Indian J Dermatol Venereol Leprol 2009; 75(2):126–35. 2.Poojabylaiah M, Marne RB, Varikkodan R, Bala N, Dandakeri S, Martis J. Relapses in multibacillary leprosy patients after Multidrug therapy. Leprosy Review 2008; 79 (3):320-324. 3. http://www.who.int/wer/2013/wer8835.pdf?ua=1 4.http://nlep.nic.in/pdf/Progress%20report%2031st%20March%202011-12.pdf 5.http://nlep.nic.in/pdf/ProgressReport2010-11.pdf 6.http://nlep.nic.in/pdf/Progress%20report%2031st%20March%202012-13.pdf 7.http://nlep.nic.in/pdf/Progress%20report%2031st%20March%202013-14.pdf 8.http://nlep.nic.in/pdf/Progress%20report%2031st%20March%202014-15%20-.pdf 9.http://nlep.nic.in/pdf/revised%20annual%20report%2031st%20March%202015-16.pdf 10.http://www.searo.who.int/entity/global_leprosy_programme/publications/8th_expert_comm_2012.pdf 11.Suzuki K, Udono T, Fujisawa M, Tanigawa K, Idani G, Ishii N. Infection during infancy and long incubation period of leprosy suggested in a case of a chimpanzee used for medical research. J Clin Microbiol 2010; 48(9):3432-3434. 12.Barker LP. Mycobacterium leprae interactions with the host cell: recent advances. Indian J Med Res 2006; 123:748-759. 13.Feldman M. The location dynamics of the US Biotech Industry: Knowledge externalities and the Anchor Hypothesis. J Industry Innovation 2003; 10 (3): 311-29. 14.Poojabylaiah M, Marne RB, Varikkodan R, Bala N, Dandakeri S, Martis J. Relapses in multibacillary leprosy patients after multidrug therapy. Lepr Rev 2008; 79(3):320–4. 15.Lwin K, Sundaresan T, Gyi MM, et al. BCG vaccination of children against leprosy: fourteen year findings of the trial in Burma. Bull World Heal Organ. 1985;63(6):1069-1078. 16. The SAGE Working Group on BCG Vaccines and WHO Secretariat. Report on BCG vaccine use for protection against mycobacterial infections including tuberculosis, leprosy, and other nontuberculous mycobacteria (NTM) infections. (available at: http://www.who.int/immunization/sage/meetings/2017/october/1_BCG_report_revised_version_online.pdf. 17.Scheelbeek PFD, Balagon MVF, Orcullo FM, Maghanoy AA, Abellana J, Saunderson PR. A Retrospective Study of the Epidemiology of Leprosy in Cebu: An Eleven-Year Profile. PLoS Negl Trop Dis 2013; 19;7(9): e2444. doi: 10.1371/journal.pntd.0002444 18.Reddy S, Brown T, Drobniewski F. Detection of Mycobacterium tuberculosis from paraffin-embedded tissues by INNO-LiPA Rif. TB assay: Retrospective analyses of Health Protection Agency National Mycobacterium R